Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Efficacy, Immunogenicity, Clinical Tolerability and Assessment of Safety of gpASIT+TM Administered Orally, According to Two Administration Schedules, for the Prophylaxis of Seasonal Grass Pollen Rhinoconjunctivitis

NCT01308021 is registered in ClinicalTrials.gov with BioTech Tools S.A. as lead sponsor.

NCT NCT01308021
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01308021 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Efficacy, Immunogenicity, Clinical Tolerability and Assessment of Safety of gpASIT+TM Administered Orally, According to Two Administration Schedules, for the Prophylaxis of Seasonal Grass Pollen Rhinoconjunctivitis
Lead sponsor
BioTech Tools S.A.
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2010
Completion date
December 31, 2011
Enrollment
202 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

grass pollen allergy, hay fever